HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
KYTX
Kyverna Therapeutics Inc
Healthcare Biotechnology · California, USA · Reports in usd
Market Cap: $492.7M
Market Cap
$492.7M
Enterprise Val
$241.9M
P/E Ratio
-3.05
P/B Ratio
2.12
Trailing PEG (1Y)
0.30
As Of
Apr 19, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value$232.3M
Return on Equity-81.41%
Return on Assets-66.65%
Current Ratio7.75
Debt/Equity0.12
LT Debt/Equity0.11
Revenue Per Share0.00

Income Statement

Dec 31, 2025
Revenue$0.00
Cost of Revenue$0.00
Gross Profit$0.00
R&D$30.0M
SG&A$9.3M
Operating Expenses$39.3M
Operating Income-$39.3M
Interest Expense$444.0K
Tax Expense$0.00
Net Income-$37.8M
EPS (Basic)$-0.79
EPS (Diluted)$-0.79
EBIT-$37.4M
EBITDA-$36.2M
Consolidated Income-$37.8M
Non-Controlling Interests$0.00

Balance Sheet

Dec 31, 2025
Cash & Equivalents$124.6M
Accounts Receivable$0.00
Inventory$0.00
Current Assets$283.0M
LT Investments$0.00
Property, Plant & Equipment$5.4M
Intangibles$0.00
Non-Current Assets$10.9M
Total Assets$293.8M
Accounts Payable$5.3M
Current Debt$4.0M
Current Liabilities$36.5M
LT Debt$25.1M
Non-Current Liabilities$25.1M
Total Liabilities$61.6M
Total Debt$29.0M
Retained Earnings-$424.8M
Shareholder Equity$232.3M
Shares Outstanding43,796,170

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow-$33.5M
Investing Cash Flow-$17.3M
Financing Cash Flow$140.7M
CapEx-$537.0K
Free Cash Flow-$34.1M
Depreciation & Amort.$1.1M
Stock-Based Comp$2.7M
Acquisitions / Disposals$0.00
Investment Activity-$16.8M
Debt Issued/Repaid$24.6M
Equity Issued/Repaid$115.8M
Dividends Paid$0.00
Net Change in Cash$89.9M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h